Clinical characteristics and burden of illness among adolescent and adult patients with severe asthma by asthma control: the IDEAL study-Reference-Cited by-同舟云学术

Clinical characteristics and burden of illness among adolescent and adult patients with severe asthma by asthma control: the IDEAL study

Published:2020-01-09 Issue:4 Volume:58 Page:459-470
ISSN:0277-0903
Container-title:Journal of Asthma
language:en
Short-container-title:Journal of Asthma

Author:

Müllerová Hana¹,Cockle Sarah M.²,Gunsoy Necdet B.³,Nelsen Linda M.⁴,Albers Frank C.⁵

Affiliation:

1. Real World Evidence, GSK, Stockley Park, Uxbridge, Middlesex, UK

2. Value Evidence and Outcomes, GSK House, Brentford, Middlesex, UK

3. Value Evidence and Outcomes, GSK, Stockley Park, Uxbridge, Middlesex, UK

4. Value Evidence and Outcomes, GSK, Collegeville, PA, USA

5. Respiratory Medical Franchise, GSK, Research Triangle Park, NC, USA

Funder

GSK

Publisher

Informa UK Limited

Subject

Pulmonary and Respiratory Medicine,Immunology and Allergy,Pediatrics, Perinatology, and Child Health

Link

https://www.tandfonline.com/doi/pdf/10.1080/02770903.2019.1708095

Reference45 articles.

1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2018. Available from: https://ginasthma.org/ [last accessed 3 December 2018].

2. Severe asthma: Lessons from the Severe Asthma Research Program

3. The prevalence of severe refractory asthma

4. An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations

5. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world biomarker variability and effects of biologics on severe asthma in Alberta;Canadian Journal of Respiratory, Critical Care, and Sleep Medicine;2024-08

2. Quality of life and work functionality in severe asthma patients: the impact of biological therapies;Journal of Occupational Medicine and Toxicology;2024-03-20

3. Burden of Uncontrolled Severe Asthma With and Without Elevated Type-2 Inflammatory Biomarkers;The Journal of Allergy and Clinical Immunology: In Practice;2023-12

5. Cost-effectiveness of tezepelumab in Canada for severe asthma;Journal of Medical Economics;2023-07-17